Pegylated synthetic human c-peptide
Also known as: C-peptide (pegylated), Long-acting C-peptide, PEG-C-peptide, PEG‑C‑peptide, Pegylated C‑peptide, Synthetic human C-peptide PEG conjugate
Source Pegylated synthetic human c-peptide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Pegylated synthetic human C‑peptide is an investigational, long‑acting analogue of the endogenous peptide co‑secreted with insulin. It is being explored as a therapeutic agent for diabetic microvascular complications, particularly peripheral neuropathy, by providing sustained C‑peptide exposure after subcutaneous or intravenous administration.
Mechanism of Action
C‑peptide binds to cell‑surface receptors that stimulate intracellular signaling cascades, leading to activation of Na⁺/K⁺‑ATPase, improved microvascular blood flow, and neurotrophic effects such as preservation of substance P and nerve fiber health. Pegylation attaches polyethylene glycol chains, extending plasma half‑life and allowing less frequent dosing while retaining receptor interactions.
What the Research Shows
Preclinical work using pegylated C‑peptide in streptozotocin‑induced diabetic mice showed that twice‑weekly dosing matched or exceeded the protective effects of twice‑daily native peptide on motor and sensory nerve conduction, thermal and tactile responses, and corneal nerve occupancy. Ex vivo studies of pegylated C‑peptide formulated in polypeptide nanospheres demonstrated increased erythrocyte Na⁺/K⁺‑ATPase activity without cytotoxicity up to 500 µg/mL. A 12‑month, placebo‑controlled clinical trial in 250 type‑1 diabetic patients receiving weekly subcutaneous pegylated C‑peptide (0.8 mg or 2.4 mg) reported a significant improvement in vibration perception threshold, while sural nerve conduction velocity and overall neuropathy scores were unchanged. Plasma C‑peptide levels rose dose‑dependently, indicating successful systemic exposure.
Reported Benefits
Evidence from animal models suggests pegylated C‑peptide can prevent or reverse functional deficits associated with diabetic neuropathy, matching native peptide efficacy with less frequent dosing. In humans, weekly administration improved vibration perception, a clinically relevant measure of sensory function, and increased circulating C‑peptide levels, supporting pharmacodynamic activity.
Limitations of the Evidence
Human data are limited to a single 52‑week trial with modest sample sizes per dose group; the primary electrophysiological endpoint (sural nerve conduction velocity) did not improve, and overall neuropathy scores were unchanged. Preclinical findings have not yet been replicated in larger, diverse patient populations, and the long‑term impact on other diabetic complications remains untested.
Safety Considerations
Preclinical nanosphere formulations showed no cytotoxicity in HEK‑293 cells up to 500 µg/mL. The clinical trial reported that safety was evaluated, but the abstract did not detail specific adverse events, implying no major safety signals were observed. Nonetheless, comprehensive safety profiling is still pending, and caution is warranted until larger studies confirm tolerability.
How It Is Administered
Pegylated C‑peptide is administered by subcutaneous injection (weekly in clinical studies) or intravenously. Formulations include the pegylated peptide alone or encapsulated within biodegradable polypeptide nanospheres designed for sustained release and prolonged stability.
Routes of Administration
Goals & Uses
- Improved pharmacokinetics over native C-peptidePharmacokinetic OptimizationModerate
- Diabetic nephropathyRenalLow
- Diabetic retinopathy preventionOphthalmological / Diabetic ComplicationLow
- Diabetic peripheral neuropathy improvementNeuroprotection / Nerve FunctionModerate
- Diabetic peripheral neuropathyNeuropathyModerate
- Diabetic nephropathy attenuationRenal ProtectionModerate
- Microvascular function restorationVascular / Diabetic ComplicationModerate
Contraindications
- Known hypersensitivity to PEGAllergyHigh
- Hypersensitivity to C-peptide or PEG excipientsAllergic / ImmunologicalHigh
- Severe renal impairmentOrganModerateKidney function concerns
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Type 2 diabetes with endogenous C-peptide productionEndocrineModerate
Adverse Effects
- Anti-PEG antibody formationImmunologicalUncommon
- HypoglycemiaMetabolicRareAbnormally low blood glucose
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- Renal PEG accumulationRenalRare
- Mild flu-like symptomsSystemicUncommon
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- Anticoagulants (e.g., warfarin)Moderate
- InsulinModerateMay increase risk of low blood sugar
- ACE inhibitors / ARBsLow
- Other PEGylated biologicsModerate
Population Constraints
- Pediatric patients (<12 yr)AgeRelative
- Pediatric populationAgeRelative
- Elderly patients (>75 years)AgeRelative
- Patients with prior severe PEG hypersensitivityImmunologicalAbsolute
- Type 1 diabetes mellitus (C-peptide deficient)Endocrine / Target PopulationAbsolute
Regulatory Status
- European UnionInvestigationalClinical trial authorization granted in several member states.
- United StatesInvestigationalUnder IND for diabetic neuropathy; not FDA‑approved.
- United KingdomInvestigationalNot approved by MHRA; research use only
No approved therapeutic use in any major jurisdiction. Investigational compound in early-phase clinical research. Not approved by FDA, EMA, or MHRA. Some formulations studied under IND or equivalent regulatory frameworks.
Evidence & Sources
- Journal ArticleLowZashikhina N, et al.2019-01-01T00:00:00.000000Z
- Journal ArticleLowJolivalt CG, et al.2015-01-01T00:00:00.000000Z
- Journal ArticleModerateWahren J, et al.2016-01-01T00:00:00.000000Z
Frequently Asked Questions
Why is pegylation used for C‑peptide?
Pegylation attaches polyethylene glycol chains to the peptide, shielding it from rapid enzymatic degradation and renal clearance. This extends the circulating half‑life, allowing less frequent dosing while preserving the peptide’s ability to engage its cellular receptors.
What diabetic complications might pegylated C‑peptide address?
Current research focuses on peripheral neuropathy, where the peptide has shown improvement in sensory thresholds. Preclinical data also suggest potential benefits for microvascular function, but evidence for other complications such as nephropathy or retinopathy is not yet available.
Is pegylated C‑peptide approved for clinical use?
No. The compound remains investigational and is being evaluated in clinical trials. It has not received regulatory approval for any indication.
How does pegylated C‑peptide differ from native C‑peptide in dosing?
Native C‑peptide typically requires multiple daily injections to maintain therapeutic levels, whereas the pegylated version achieved comparable or superior effects with twice‑weekly (in mice) or once‑weekly (in humans) subcutaneous dosing due to its prolonged half‑life.
What are the known side effects of pegylated C‑peptide?
The published clinical trial abstract did not report specific adverse events, and preclinical studies showed no cytotoxicity at tested concentrations. However, comprehensive safety data are limited, and potential side effects remain to be fully characterized.
What is Pegylated synthetic human c-peptide?
Pegylated synthetic human C‑peptide is an investigational, long‑acting analogue of the endogenous peptide co‑secreted with insulin. It is being explored as a therapeutic agent for diabetic microvascular complications, particularly peripheral neuropathy, by providing sustained C‑peptide exposure after subcutaneous or intravenous administration.
What is Pegylated synthetic human c-peptide used for?
Pegylated synthetic human c-peptide is educationally associated with: Improved pharmacokinetics over native C-peptide, Diabetic nephropathy, Diabetic retinopathy prevention, Diabetic peripheral neuropathy improvement, Diabetic peripheral neuropathy, Diabetic nephropathy attenuation, Microvascular function restoration. Educational only — not medical advice.
How is Pegylated synthetic human c-peptide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Pegylated synthetic human c-peptide?
Reported adverse effects include: Anti-PEG antibody formation, Hypoglycemia, Injection site reactions, Headache, Renal PEG accumulation, Mild flu-like symptoms, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Pegylated synthetic human c-peptide?
Recorded contraindications: Known hypersensitivity to PEG, Hypersensitivity to C-peptide or PEG excipients, Severe renal impairment, Pregnancy, Type 2 diabetes with endogenous C-peptide production. Consult a qualified clinician before use.